[1]
de Portu, S. et al. 2009. Economic evaluation of temsirolimus on the basis of the results of the ARCC (Advanced Renal-Cell Carcinoma) study. Farmeconomia. Health economics and therapeutic pathways. 10, 2 (Jun. 2009), 93–97. DOI:https://doi.org/10.7175/fe.v10i2.167.